0GQU Stock Chart & Stats
kr0.04
kr0.01(10.43%)
At close: 4:00 PM EST
kr0.04
kr0.01(10.43%)
Day’s Range― - ―
52-Week Rangekr3.50 - kr8.64
Previous CloseN/A
Volume200.00K
Average Volume (3M)95.00
Market Cap
kr85.01M
Enterprise Valuekr106.98M
Total Cash (Recent Filing)kr43.90M
Total Debt (Recent Filing)kr100.00K
Price to Earnings (P/E)―
Beta1.68
Next Earnings
Nov 05, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.39
Shares Outstanding26,360,670
10 Day Avg. Volume85
30 Day Avg. Volume95
Financial Highlights & Ratios
PEG Ratio2.36
Price to Book (P/B)111.47
Price to Sales (P/S)0.00
P/FCF Ratio-191.29
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)kr21.50M
Bulls Say, Bears Say
Bulls Say
Very Low LeverageVery low debt reduces mandatory financing costs and leaves the company less exposed to refinancing pressure. This provides greater flexibility to allocate available capital toward clinical development and partnerships, although it does not eliminate the need to fund ongoing operating losses.
Narrowing Net LossesThe multi-year reduction in net losses indicates some improvement in cost control or development spending efficiency. If sustained, this trend could extend the company’s funding runway and reduce the pace at which external capital is required to advance its therapeutic pipeline.
Improving Cash-burn TrendOperating cash consumption has decreased materially from earlier periods, showing that the company is controlling cash outflows even while remaining loss-making. Continued improvement would support a longer runway and give management more time to create value from clinical programs or partnerships.
Bears Say
No Reported RevenueZero reported revenue means the business has not yet demonstrated commercial monetization of its therapeutic pipeline. Without product, licensing, milestone, or collaboration revenue reflected in the results, future funding remains dependent on advancing assets toward value-creating transactions or eventual commercialization.
Persistent Cash ConsumptionConsistently negative operating and free cash flow shows that the company is consuming capital rather than funding development internally. This creates ongoing dependence on financing, partnerships, or other strategic transactions and could constrain the pace of pipeline advancement if funding becomes less available.
Declining Equity And Dilution RiskFalling equity alongside persistently negative returns indicates that losses are eroding the capital base. If this continues, the company may need additional financing to sustain operations, creating the dilution risk and reduced financial flexibility identified in the balance-sheet assessment.
Active Biotech AB News
0GQU FAQ
What was Active Biotech AB’s price range in the past 12 months?
Active Biotech AB lowest share price was kr3.50 and its highest was kr8.64 in the past 12 months.
What is Active Biotech AB’s market cap?
Active Biotech AB’s market cap is kr85.01M.
When is Active Biotech AB’s upcoming earnings report date?
Active Biotech AB’s upcoming earnings report date is Nov 05, 2026 which is in 14 days.
How were Active Biotech AB’s earnings last quarter?
Active Biotech AB released its earnings results on Aug 20, 2026. The company reported -kr0.383 earnings per share for the quarter.
Is Active Biotech AB overvalued?
According to Wall Street analysts Active Biotech AB’s price is currently Overvalued.
Does Active Biotech AB pay dividends?
Active Biotech AB does not currently pay dividends.
What is Active Biotech AB’s EPS estimate?
Active Biotech AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Active Biotech AB have?
Active Biotech AB has 26,360,670 shares outstanding.
What happened to Active Biotech AB’s price movement after its last earnings report?
Active Biotech AB reported an EPS of -kr0.383 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Active Biotech AB?
Currently, no hedge funds are holding shares in GB:0GQU
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Active Biotech AB
Active Biotech AB (publ), a biotechnology company, engages in the research, development, production, marketing, and sale of medical, chemical, and biotechnology products in Sweden. It is developing Tasquinimod, a small molecule immunomodulator, which is in Phase II clinical trial to treat hematological malignancies; Laquinimod, an immunomodulator for the treatment of severe inflammatory eye diseases, such as non-infectious non anterior uveitis; and Naptumomab estafenatox, a tumor targeting immunotherapy to treat patients with solid tumors. The company has collaboration with Abramson Cancer Center, University of Pennsylvania, MD Anderson Cancer Center, Texas and Stictching-Haemato-Oncologie Volwassenen Netherlands, as well as Stanford Medicine and the Global Ophthalmic Research Center. The company was incorporated in 1983 and is headquartered in Lund, Sweden.
Technical Analysis
Hansa Biopharma AB
―
BioInvent International AB
―
Oncopeptides AB
―
SynAct Pharma AB
―
Cantargia AB
―